Literature DB >> 9816310

Immunohistochemical detection of K-sam protein in stomach cancer.

Y Hattori1, H Itoh, S Uchino, K Hosokawa, A Ochiai, Y Ino, H Ishii, H Sakamoto, N Yamaguchi, K Yanagihara, S Hirohashi, T Sugimura, M Terada.   

Abstract

The K-sam gene, originally isolated as an amplified gene from the stomach cancer cell line KATO-III, is characterized by its preferential amplification in the undifferentiated type (diffuse type) of stomach cancer and encodes one of the receptors for heparin-binding growth factors or fibroblast growth factors. The K-sam gene has been isolated by different methods and has been designated BEK, TK14, and Cek2. The receptor for keratinocyte growth factor was also found to be encoded by the same gene. To examine the expression of the K-sam protein in stomach cancer, polyclonal antibody pK1-2 was raised against the extracellular domain of the gene product. This antibody detected K-sam proteins by Western blot and flow cytometry analyses in stomach cancer cell lines KATO-III and HSC39, in which the K-sam gene is amplified and overexpressed. By immunohistochemical analysis, 20 of 38 cases of the undifferentiated type of advanced stomach cancer were K-sam positive, whereas none of 11 cases of the differentiated or intestinal type revealed K-sam staining. The K-sam product was observed predominantly in diffusely infiltrative lesions. In one autopsy case, the K-sam protein was detected only focally in the primary tumor, whereas markedly increased staining for the K-sam product was detected diffusely in the metastasized tumor in the lymph node and liver. These results suggest that K-sam overexpression is associated with the malignant phenotype of the undifferentiated type of stomach cancer, such as infiltrative growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816310

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

Review 1.  Current status of novel agents in advanced gastroesophageal adenocarcinoma.

Authors:  Nishi Kothari; Khaldoun Almhanna
Journal:  J Gastrointest Oncol       Date:  2015-02

2.  Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts.

Authors:  Wei-meng Zhao; Lihong Wang; Hangil Park; Sophea Chhim; Melanie Tanphanich; Masakazu Yashiro; K Jin Kim
Journal:  Clin Cancer Res       Date:  2010-07-29       Impact factor: 12.531

3.  Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Authors:  Hilda Wong; Thomas Yau
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

4.  Competition between Grb2 and Plcγ1 for FGFR2 regulates basal phospholipase activity and invasion.

Authors:  Zahra Timsah; Zamal Ahmed; Chi-Chuan Lin; Fernando A Melo; Loren J Stagg; Paul G Leonard; Prince Jeyabal; Jonathan Berrout; Roger G O'Neil; Mikhail Bogdanov; John E Ladbury
Journal:  Nat Struct Mol Biol       Date:  2014-01-19       Impact factor: 15.369

Review 5.  Current advances of targeting HGF/c-Met pathway in gastric cancer.

Authors:  Aristomenis Anestis; Ilianna Zoi; Michalis V Karamouzis
Journal:  Ann Transl Med       Date:  2018-06

6.  Cancer-stromal interactions in scirrhous gastric carcinoma.

Authors:  Masakazu Yashiro; Kosei Hirakawa
Journal:  Cancer Microenviron       Date:  2010-01-26

Review 7.  Advances of Molecular Targeted Therapy in Gastric Cancer.

Authors:  Bulent Cetin; Ozge Gumusay; Mustafa Cengiz; Ahmet Ozet
Journal:  J Gastrointest Cancer       Date:  2016-06

Review 8.  Targeted therapies in gastric cancer treatment: where we are and where we are going.

Authors:  Gianluca Tomasello; Michele Ghidini; Wanda Liguigli; Margherita Ratti; Laura Toppo; Rodolfo Passalacqua
Journal:  Invest New Drugs       Date:  2016-02-12       Impact factor: 3.850

Review 9.  Molecular targeted agents for gastric and gastroesophageal junction cancer.

Authors:  Takashi Oshima; Munetaka Masuda
Journal:  Surg Today       Date:  2011-11-30       Impact factor: 2.549

Review 10.  New advances in targeted gastric cancer treatment.

Authors:  Daniela Cornelia Lazăr; Sorina Tăban; Marioara Cornianu; Alexandra Faur; Adrian Goldiş
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.